TY - JOUR T1 - Review: several pharmacological therapies promote modest weight loss JF - Evidence Based Medicine JO - Evid Based Med SP - 140 LP - 140 DO - 10.1136/ebm.10.5.140 VL - 10 IS - 5 A2 - , Y1 - 2005/10/01 UR - http://ebm.bmj.com/content/10/5/140.abstract N2 - Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532–46.OpenUrlCrossRefPubMedWeb of Science 
 
 Q How effective and safe are pharmacological therapies in the treatment of obesity? Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★☆☆ Endocrine ★★★★★☆☆ Data sources: Medline (to July 2003), the Cochrane Central Register of Controlled Trials, and existing systematic reviews. Study selection and assessment: randomised controlled trials that evaluated pharmaceutical agents for weight loss in patients with body mass index ⩾27 kg/m2 and reported ⩾6 month weight outcomes. Study quality was assessed using the 5 point Jadad scale (5 = highest quality) and considered study design, method of random assignment, blinding, and withdrawal. Outcomes: weight loss and side effects. The studies meeting inclusion criteria were 3 existing meta-analyses (39 RCTs) evaluating sibutramine, phentermine, and diethylpropion, and 47 RCTs that evaluated orlistat, bupropion, topiramate, and fluoxetine. All comparisons were with placebo, and most trials had a hypocaloric diet cointervention. Meta-analyses were done … ER -